L3Harris After the Pullback: Three Engines, One Investable Thesis
L3Harris Technologies (NYSE: LHX) reported strong first quarter 2026 results, with orders of $7.8 billion and a book-to-bill ratio of 1.4x, increasing the backlog to a new record of $40.7 billion. Revenue reached $5.7 billion, up 12%, and 15% organically. The operating margin was 11.4%, up 120 basis points, and the segment operating margin was 15.7%, up 10 basis points. GAAP diluted EPS was $2.72, up 33%.
L3Harris posted $5.74 billion in Q1 2026 revenue, up 12% year over year, with diluted EPS of $2.72—beating consensus estimates by approximately 6% on revenue and nearly 8% on earnings. All three segments grew, and contractual backlog reached a record $40.7 billion.
The breadth of the beat matters more than the magnitude. Two of L3Harris's three newly realigned segments delivered double-digit revenue growth, and all three expanded operating margins by at least 60 basis points. Consolidated operating margin rose from 10.2% to 11.4%, producing $652 million in operating profit. Segment operating margins have now expanded for ten consecutive quarters—a streak that speaks to execution rather than luck.
Management highlighted that revenue has grown organically in nine of the last ten quarters, a track record unusual for a company of this size and complexity. After the quarter, management raised full-year GAAP EPS guidance by $0.10 to $11.40–$11.60, reaffirmed revenue of $23.0–$23.5 billion (representing 7% organic growth at the midpoint), maintained segment operating margins at low 16%, and reiterated $3 billion in free cash flow, weighted to the back half. New CFO Ken Sharp noted there is "a level of conservatism" in the outlook—language that historically precedes upward revisions.
Three Segments, Three Distinct Value Drivers
L3Harris restructured into three segments at the start of fiscal 2026. Each carries its own growth profile, margin trajectory, and investment case.
Space & Mission Systems: The Growth Flywheel
SMS is the largest segment, guided to approximately $11.5 billion in 2026 revenue. It integrates satellites, ISR aircraft missionization, maritime systems, and classified programs. Q1 revenue of $2.99 billion rose 24% year over year—a remarkable clip for a business of this scale—driven by classified program ramps, Space Development Agency satellite awards, and international ISR demand.
Management says it can missionize a commercial aircraft in 18 months, a speed advantage that resonates in a procurement environment that prizes urgency. Classified work now represents approximately 28% of the company, up from the prior year, and a recent $600 million sole-source classified award carries potential for billions in follow-on value.
The knock on SMS: margins in the mid-10% range remain below group average. Cost-type prime work in space and ISR inherently produces thinner margins than product-centric businesses. The key variable to watch is margin progression as development contracts transition to production and SDA constellation work scales.
Communications & Spectrum Dominance: The Margin Anchor
CSD is the segment most responsible for L3Harris's premium valuation. It houses the company's crown-jewel tactical radio franchise, broadband electronic warfare systems, electro-optical sensors, and public safety communications—guided to approximately $8 billion in 2026 revenue at a 25% segment margin.
That 25% margin target is striking for a defense company and more reminiscent of a commercial technology franchise. The economic engine is an installed base of roughly one million software-defined radios deployed worldwide. The radios generate recurring revenue through software upgrades, waveform licensing, and life-cycle sustainment—a model closer to enterprise software than traditional defense hardware. Management expects the installed base to grow by 20% over the next two years.
The international book-to-bill ratio reached 2.2x in Q1—a powerful leading indicator. NATO allies are spending urgently on interoperable communications, and L3Harris's Link 16 and advanced waveform capabilities position it as the default provider. Some investors worry about a domestic radio procurement taper, but the international pipeline and NATO's expanding defense budgets provide a long runway.
Missile Solutions: The Capacity Cycle
MSL is the most dynamic—and most debated—segment. It consolidates the legacy Aerojet Rocketdyne propulsion business with missile-related capabilities, including seekers, fuzing, and air-launched effects. Guided to approximately $4.4 billion in 2026 revenue at mid-12% margins, management targets approximately $6.3 billion in MSL revenue by 2028, implying a high-teens compound annual growth rate.
L3Harris is investing billions to expand production for programs including PAC-3, THAAD, Tomahawk, and Standard Missile. Industry-wide, production rates for critical munitions programs are ramping sharply to meet allied demand, and the Pentagon is funding capacity buildouts with an urgency not seen in decades.
The marquee catalyst is the $1 billion Department of War investment, which closed in April 2026. Structured as a convertible preferred security that converts to common equity at an IPO, the capital will fund facility expansions at Camden (Arkansas), Huntsville (Alabama), and Orange (Virginia). L3Harris will retain more than 80% ownership of the business after any listing.
Management has also cited $25 billion in potential orders from the Munitions Acceleration Council framework currently under negotiation—not yet included in backlog. If even a fraction converts, the MSL order book could step-change higher.
The IPO: Catalyst or Complication?
L3Harris has filed a confidential Form S-1 for the IPO of its Missile Solutions business, which will trade under the name "Axyz." Timing is targeted for the second half of 2026, contingent on market conditions.
The structure is novel for defense. The DoW's $1 billion preferred security converts to common equity at the IPO at an 80% conversion rate relative to the IPO price, and the government receives warrants granting it a single-digit equity stake. L3Harris retains controlling interest exceeding 80%.
For LHX shareholders, this is both opportunity and risk. On the opportunity side, a public listing creates a transparent valuation marker for the fastest-growing piece of the portfolio—potentially highlighting value currently obscured in LHX's consolidated multiple. On the risk side, IPO execution in volatile markets is uncertain, governance becomes more complex with a DoW co-investor, and questions about proceeds allocation and whether value leaks to the new vehicle will linger.
Critically, management has confirmed that 2026 guidance and the 2028 framework continue to include Missile Solutions as currently structured. The earnings path does not depend on the IPO closing. If it slips, L3Harris simply retains the cash flow and growth internally—an asymmetry worth noting.
At approximately $315 per share and a $58 billion market capitalization, LHX trades at roughly 27x the midpoint of 2026 GAAP EPS guidance ($11.50) and approximately 19x its $3 billion free cash flow target.
That is a premium to peers like Lockheed Martin (~18x forward earnings) and Northrop Grumman (~20x), but it reflects faster organic growth—7% company-wide, with Missile Solutions growing considerably faster—a margin profile anchored by CSD's 25% operating margins, and the optionality embedded in MSL's capacity ramp. Bernstein analyst Douglas Harned maintains an Outperform rating with a $405 price target, implying roughly 29% upside, while Deutsche Bank's $300 target and Hold rating suggest modest downside.
A sum-of-the-parts framework is instructive. If CSD's $8 billion revenue base deserves a mid-20s multiple on roughly $2 billion in segment operating income, that alone accounts for a substantial share of enterprise value. SMS at a market-average defense multiple and MSL at a growth-adjusted multiple suggest the consolidated stock is trading at a discount to the sum of its parts—a gap the Axyz IPO could help close.
On a free cash flow yield basis, approximately 5.1% ($3 billion on a $58 billion market cap) is reasonable for a defense company generating strong organic growth. Capital return continues: the quarterly dividend was recently raised to $1.25 per share ($5.00 annualized, a yield of roughly 1.6%), and approximately $1.9 billion of share repurchase authorization remains.
The Bear Case, Honestly Stated
Four risks deserve serious consideration:
Fixed-price exposure. In fiscal 2025, 75% of revenue derived from fixed-price contracts. A negative EAC adjustment on a classified Maritime program cost $38 million in fiscal 2025. MSL margins were partially helped by a legacy asset sale in Q1 2026—stripping that out, underlying margins look thinner. One or two program hiccups can erase a quarter's margin expansion.
IPO execution risk. The Axyz IPO introduces structural complexity. If market conditions deteriorate, the listing may slip. Even if it proceeds, debates about governance, dilution from DoW warrants, and the appropriate multiple for a defense propulsion company could create overhang for LHX shares.
Space margins and competition. SMS carries the lowest margins of any segment, and the business involves heavy prime-contractor competition in areas like proliferated LEO constellations. Competitors are aggressive on pricing, and Europe's growing emphasis on local content adds friction to the international ISR pipeline.
Budget risk, always. While the backlog insulates near-term revenue, L3Harris still derives 75% of revenue from U.S. Government customers. Changes in appropriations priorities, continuing resolutions, or a shift in geopolitical posture that reduces missile urgency would weigh on sentiment and potentially on bookings.
Balance Sheet: Serviceable, Not Pristine
Long-term debt stands at approximately $11 billion, a legacy of the Aerojet Rocketdyne acquisition, partly offset by $590 million of cash as of the first quarter. Interest expense declined 12% in fiscal 2025 as commercial paper balances fell, and the company has manageable near-term maturities, including $550 million due in December 2026. The pension position improved meaningfully, with net defined benefit plan assets rising to $1.2 billion at year-end from $789 million a year earlier—reducing a historical source of balance-sheet volatility.
Catalysts on the Horizon
Several near-term developments could re-rate the stock:
- MAC framework formalization. Management expects to finalize Munitions Acceleration Council agreements later this year, potentially adding billions to backlog.
- Axyz IPO pricing. A successful listing in the second half of 2026 would crystallize MSL's standalone value and draw new investor interest to LHX.
- SDA and space-sensing follow-on awards. L3Harris holds strong positions in proliferated space sensing and tracking. Award announcements would demonstrate pipeline conversion.
- Q2 earnings (estimated late July). With management's acknowledged conservatism in guidance, the Q2 print could provide another margin and revenue beat, reinforcing the operating momentum narrative.
The stock's retreat from $379 to approximately $315 coincides with broad defense sector weakness and normal post-run profit-taking—not with any deterioration in fundamentals. The pullback has compressed the forward P/E from roughly 33x at the peak to 27x today, while the earnings base has simultaneously risen.
Bottom Line
L3Harris is executing a portfolio transformation at the right moment in the defense cycle. Its three-segment structure neatly separates the growth engine (SMS), the cash cow (CSD), and the capacity-cycle story (MSL), each with distinct value propositions. Record backlog provides unusual revenue visibility. Margins are expanding, guidance has been raised, and hard catalysts—MAC framework awards, the Axyz IPO, and pending SDA contracts—lie directly ahead.
The risks are real: fixed-price contract exposure, IPO complexity, and budget uncertainty deserve monitoring. But the spring pullback has created a more favorable entry point. For investors with a 12-month horizon and tolerance for defense-sector volatility, L3Harris offers a rare combination of growth, margin quality, and visible catalysts at a reasonable price. The setup favors patient buyers.
Disclosure: This article is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making investment decisions.